Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02699593 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of Approved Contact Lenses
A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 142
- Enrollment target
- 7
- Study locations
NCT02699593: Completed NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT02699593 is a NA study of Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 20 other Visual Acuity trials with a reported enrollment target. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02699593, a NA study of Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a 4-week, randomized, double-masked study where subjects will wear bilaterally test and control lenses in random succession. The objective is to evaluate materials from different suppliers.
Primary Outcome
Contact lens wearing time was collected for each subject at the 2-week follow-up evaluation. The average contact lens wearing time in hours was reported for each lens.
Conditions Studied
Interventions
- DEVICE Test Contact Lens
- DEVICE Control Contact Lens
Study Locations (7)
Florida
- Eye Elements Eyecare - Jacksonville
- Golden Vision - Sarasota
Alabama
- University of Alabama at Birmingham - Birmingham
Kansas
- Advantage Eyecare Associates, LLC - Neodesha
Missouri
- Advanced Eyecare, PC - Raytown
Ohio
- Professional Vision Care - Westerville
Virginia
- Timothy R. Poling, OD - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2016-04-01 |
| Phase | NA |
What the finished NCT02699593 record still lists
NCT02699593 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 20 other Visual Acuity trials with a reported enrollment target.
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions - of which Test Contact Lens is the first listed.
NCT02699593 lists 7 locations in 6 states (Florida, Alabama, Kansas).
Frequently Asked Questions
What is clinical trial NCT02699593 about?
NCT02699593 is a clinical study titled "Clinical Evaluation of Approved Contact Lenses". This is a 4-week, randomized, double-masked study where subjects will wear bilaterally test and control lenses in random succession. The objective is to evaluate materials from different suppliers.
What is the current status of trial NCT02699593?
This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2016-02-01. Estimated completion is 2016-04-01.
What conditions does trial NCT02699593 study?
This clinical trial studies the following conditions: Visual Acuity.
What interventions are being tested in trial NCT02699593?
The interventions under investigation include: Test Contact Lens (DEVICE), Control Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT02699593?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02699593 being conducted?
This trial has 7 study locations across Alabama, Florida, Kansas, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Acuity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02699593's enrollment target sits among peer trials
142 6th of 20 higher than 15 of 20 other Visual Acuity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Effect of Scatter on Visual Performance
RECRUITING · NA
-
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
COMPLETED · NA
-
Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
COMPLETED · NA
-
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
COMPLETED · NA
-
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
COMPLETED · NA
-
Clinical Evaluation of Manufacturing Processes for a Reusable Multifocal Optical Design in a Presbyopic Population
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI